-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although severe systemic fungal infections are rare, a growing body of research shows that fungal tolerance to drugs is increasing.
invasive fungal infections are an important cause of death in patients with HIV infections, tumors, and damaged immunity such as organ transplants.
, on the other hand, there have been no new drugs in the antifungal field since the first echinocrine drugs were approved 20 years ago.
This is mainly because, unlike bacteria, fungi are funnel organisms, and many potential targets that are critical to fungal growth or reproduction have similar effects to humans and therefore cannot actually be used as drug targets.
F2G has discovered and developed a new antifectant called orotomides, which selectively targets the fungus dihydroclic acid dehydrogenase (DHODH), which is lethal to a wide range of rare and drug-resistant fungal infections.
F2G's first drug candidate, ololofim (F901318), is currently in the clinical phase 2b open label phase for the treatment of rare and drug-resistant invasive fungal infections, such as invasive cryptobacteria (including resistant strains of pyridoxine), cedococcal disease, refilm spores, sickle disease, membrane cystic disease and spores (glycosis).
, the European Medicines Agency has granted olorofim orphan drugs for the treatment of invasive asmycin and spore worm disease.
year, the FDA also awarded olorofim breakthrough therapy, making it the first antifellar drug to be recognized as a breakthrough therapy.
molecular structure of Olorofim (Photo: F2G website) Pathogenic microorganisms have been one of the factors that endanger our health, and with the extensive use of antimicrobials, the resistance of pathogenic microorganisms has increased rapidly worldwide.
years, multi-drug-resistant bacteria, wide-ranging drug-resistant bacteria, pan-resistant bacteria continue to appear, the market for new antimicrobials, especially new broad-spectrum antimicrobials demand has not been met.
the FDA has also approved a variety of new antibiotics in recent years, including Sulopenem of Itrum Threapeutics, Eravacycline of Tetraphase Pharmaceuticals and Recarbrio of Merca East.
same time, large multinational pharmaceutical companies are actively expanding, and in May, Amlyx in San Diego announced a $93 million round of C financing from Pfizer to advance the second phase of its broad-spectrum antifulgic drug fosmanogepix (APX001).
academic community is also actively applying AI, genomics and other new technologies to explore ways to discover new antimicrobial drugs, many high-quality projects eventually set up companies to promote the commercialization of projects.
F2G, which has just been financed, is a new company that has left the University of Manchester.
we look forward to more new antimicrobials in the future, driven by capital.
: s1. F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent. Retrived August 12, 2020, from.